Under the boom of pharmaceutical companies deploying AI, a number of companies have begun to usher in new breakthroughs

【Pharmaceutical Network Market Analysis】In recent years, the layout of AI by pharmaceutical companies has become an industry boom, especially with the help of AI, drug discovery and preclinical stage can save 40%-50% of time, saving 26 billion US dollars per year; 50%-60% time savings in clinical stage, saving $28 billion per year; At present, the global AI pharmaceutical industry is accelerating its development
.
Pharmaceutical companies have become an upsurge in the layout of AI, and a group of companies have begun to usher in breakthroughs (Image source: Pharmaceutical Network) Layout AI has become an important part of the competition of pharmaceutical companies Data show that from 2014 to 2021, the amount of investment in the field of AI pharmaceuticals has increased by 15 times
.
In China, although AI pharmaceuticals started late, they have developed very fast in recent years, and a large number of listed pharmaceutical companies, medical institutions, universities, Internet giants and start-ups have begun to lay out AI pharmaceutical tracks
.
According to statistics, there are currently more than 60 AI pharmaceutical companies in China, including Insilico, XtalPi and so on
.
Before 2020, there were less than 10 AI pharmaceutical companies
in the country.
Since the beginning of this year, a large number of pharmaceutical companies are accelerating the layout of AI pharmaceutical fields
.
For example, on August 9, Antengene announced that it has reached a long-term strategic cooperation with AI drug research and development company Deruizhi Pharma to jointly promote the research and development
of the first small molecule anti-tumor innovative drug.
On July 25, Yunnan Baiyao announced that the company will cooperate with Huawei to carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development, explore mechanisms for joint scientific research and innovation, and expand the breadth and depth of cooperation between the two sides, including but not limited to large and small molecule design, related diseases, database development, etc
。 On January 11, Fosun Pharma and Insilico, an end-to-end AI-driven drug discovery company, announced a collaboration and nominated the preclinical candidate compound ISM004-1057D for new tumor immunotherapies in less than 40 days.
.
.
With the help of AI, pharmaceutical companies are constantly ushering in new breakthroughs It is worth mentioning that with the help of AI, many companies have ushered in new breakthroughs in new drug research and development
.
In May this year, ISM001-055, the world's first new drug candidate discovered and designed by Insilico through an artificial intelligence platform, entered phase I clinical trials in China, and completed the dosing
of the first healthy subjects in July.
This is the first drug discovered and designed by artificial intelligence to enter clinical trials in China for the treatment of idiopathic pulmonary fibrosis disease
.
In this project, Insilico completed only 18 months from target discovery to preclinical drug candidate, with a research and development investment of only millions of dollars
.
It is worth mentioning that Insilico also recently announced that it has reached a drug research and development cooperation with Sanofi that will last for many years and target multiple targets, which means that domestic AI pharmaceutical companies have begun to be recognized by large pharmaceutical companies and gradually move towards the international stage
.
In addition to ISM001-055, in September this year, Professor Liu Bing's team from the First Affiliated Hospital of Xi'an Jiaotong University also broke through the development of a super antibacterial drug Drug X, which is expected to become the world's first new target and new class of antibiotics
in nearly 40 years.
It is reported that Drug X series is a super antibacterial drug successfully developed by using AI-assisted drug
design services based on the large model of drug molecules in HUAWEI CLOUD Pangu.
With the help of HUAWEI CLOUD Pangu Drug Molecule Model, the R&D cycle of the drug has been shortened from several years to one month, and the R&D cost has been reduced by 70%.

From the above point of view, the investment and layout of artificial intelligence has become an important part
of the competition of leading pharmaceutical companies.
Although AI technology has not yet reached a revolutionary breakthrough in the pharmaceutical industry, there are still many important problems to be solved in the field of research and development; However, with the continuous accumulation and improvement of AI technology and biomedical technology, the industry expects that there will be more and more
innovative drugs aimed at solving clinical needs.
The future of AI pharmaceuticals will continue to achieve the development model
of "from 1 to N" with the breakthrough of data algorithms.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.